Navigation Links
RVX-208 Data Demonstrates Increase in Functional HDL Particles
Date:11/10/2008


Prebeta-HDL generation and improved HDL functionality are distinguishing

factors

TSX Exchange Symbol: RVX

NEW ORLEANS, LA, Nov. 10 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) is pleased to announce today key scientific data was presented in an oral presentation highlighting the novel features of RVX-208 at the American Heart Association Scientific Meeting. The presentation titled "Compound RVX-208 Modulates HDL-C Levels and Function in Non-human Primates and in Early Human Trials" was presented by Dr. Jacques Genest.

Dr. Jacques Genest, MD, Director of the Division of Cardiology at McGill University Health Centre/Royal Victoria Hospital said, "We continue to be excited about the data that is being generated for RVX-208. It is important that our colleagues have access to this promising data which is why we have presented at this prominent conference. Resverlogix's novel drug demonstrated the ability to increase the production of ApoA-I and functional HDL. Notably we saw increases in prebeta-HDL particles, which improve HDL's ability to mediate cholesterol efflux."

"Today we presented interesting and consistent data from African Green monkey studies and our Phase 1a human clinical trial at the AHA," stated Dr. Jan Johansson, MD, Ph.D., Senior Vice President, Medical Affairs of Resverlogix. "The pharmacodynamic data from human healthy volunteers of which the majority had low HDL demonstrated that we have seen significant increases in ApoA-I production and HDL functionality, consistent with previous findings in the African Green monkey studies. Further investigation of the effect of RVX-208 on the HDL metabolic pathway is ongoing in humans and animals to establish the mechanisms of action and therapeutic potential in treating atherosclerotic cardiovascular disease."

During the presentation Dr. Genest reported that in an African Green monkey study treatment with RVX-208 resulted in a highly
'/>"/>

SOURCE Resverlogix Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. RVX-208 Exploratory Study Illustrates Early Potential for Alzheimers Disease
2. International Steering Committee for RVX-208 IVUS Trial Formed
3. Phase 1b/2a Program Commences for RVX-208
4. Industry Leaders Select Resverlogixs RVX-208
5. Dosing for RVX-208 Phase 1a Clinical Study Completed
6. FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX-208
7. Reverse Cholesterol Transport by RVX-208 a Small Molecule for ApoA-I Production Increase Presented at American Heart Association Scientific Meeting
8. Study From the University of Texas M.D. Anderson Cancer Center Demonstrates That AHCC(R) is Safe in Combination With Most Chemotherapeutic Agents
9. Vaxart Demonstrates Efficacy of Oral Avian Flu Vaccine in Preclinical Studies
10. EntreMeds ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model
11. SuperGens MP-470 Demonstrates Clinical Tumor Regression When Combined with Standard of Care Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... , July 25, 2014  Galmed Pharmaceuticals Ltd. (Nasdaq: ... focused on the development and commercialization of a once-daily, ... cholesterol gallstones, today announced financial results for the period ... Financial Summary: , Reported cash and cash equivalents ... $137,000 at December 31, 2013.  , Reported a ...
(Date:7/25/2014)... July 25, 2014 Sinovac Biotech Ltd. (Nasdaq: ... China , today announced that it will ... June 30, 2014, after market close on Thursday, August 14, ... to the market opening on Friday, August 15, 2014, at ... China Standard Time) to review the Company,s financial results and ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 Gain ... Global Supply Chain of the biotech industry. Nominations ... Innovation Awards, brought to you by the ... organization of supply chain management professionals for the ... to stakeholders of the Biotech industry – Manufacturers, ...
(Date:7/24/2014)... 2014  ECC West Africa, LLC (ECC) signed a ... University College Hospital (UCH) Ibadan Board of Management for ... design, construct, and operate and maintain a new, state-of-the-art ... Under the first of the 4-phase project, ECC will ... applications. UCH Ibadan intends to finance and develop the ...
Breaking Biology Technology:Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 3ECC Signs a Contract for the Finance, Design, and Construction of a Premier Cancer Institute in Ibadan, Nigeria 2
... July 27, 2011 /PRNewswire/ -- bioTheranostics, a ... support targeted disease management, announced today study results published ... Molecular Diagnostics related to the clinical validity and ... classification test to aid in the determination of the ...
... Midwest health care startups reported $315 million in total ... 2011, according to the BioEnterprise Midwest ... ) "While the number of companies funded ... dollars invested is down compared to recent years," said ...
... CHICAGO, July 26, 2011 Linden LLC, a ... it has made an investment in Strata Pathology ... in New England. Headquartered in Lexington, ... dermatology, urology, podiatry, oral pathology, gastroenterology and gynecology ...
Cached Biology Technology:New Study Reports CancerTYPE ID Expands Tumor Type Coverage and Demonstrates Clinical Utility 2New Study Reports CancerTYPE ID Expands Tumor Type Coverage and Demonstrates Clinical Utility 3Midwest Health Care Startups Raise $315 Million in First Half of 2011 2Midwest Health Care Startups Raise $315 Million in First Half of 2011 3Midwest Health Care Startups Raise $315 Million in First Half of 2011 4Linden Enters Anatomic Pathology Sector Through Investment in Strata Pathology Services, Inc. 2
(Date:7/25/2014)... of diffusion tensor tractography (DTT), which is derived ... estimation for three motor tracts, such as the ... pathway became possible. The corticospinal tract is known ... function in the human brain. Several studies have ... transtentorial herniation. In addition, some studies have demonstrated ...
(Date:7/25/2014)... 2014 Biometrics industry expands and ... digital technology for online & commerce payments while seeking ... GOOG ), LifeLock Inc. (NYSE: ... Apple Inc. (NASDAQ: AAPL ) and Fortinet ... a biometric authentication company focused on the growing m-commerce ...
(Date:7/24/2014)... NY (July 24, 2014) Scientists at The ... are one step closer to creating a viable ... patient,s own cells. , For the first ... cells lines from skin samples of patients with ... an accelerated protocol to induce these stem cells ...
Breaking Biology News(10 mins):Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 2Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 3Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 4Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 5Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 6NYSCF scientists 1 step closer to cell therapy for multiple sclerosis patients 2
... Bethesda, MD (July 29, 2010): Today, the Association for Molecular ... for Information made by the National Institutes of Health (NIH) ... survey of its membership to formulate a comprehensive response to ... in a clinical laboratory setting, AMP is able to inform ...
... call "white graphene" may be the perfect sidekick for ... nanoscale electronics. But single-atom-thick layers of hexagonal boron ... University,s world-class Department of Mechanical Engineering and Materials Science, ... Researchers in the lab of Pulickel Ajayan, Rice,s ...
... CA July 28, 2010 For Immediate Release ... normally produced in the brain may provide the starting point ... epileptic seizures, according to a new study by scientists at ... a new angle for developing drugs to treat seizures," says ...
Cached Biology News:AMP responds to Genetic Test Registry request for information 2'White graphene' to the rescue 2Scripps research study opens the door to new class of drugs for epileptic seizures 2Scripps research study opens the door to new class of drugs for epileptic seizures 3
Mouse monoclonal [3G8] to MDMA ( Abpromise for all tested applications)....
Fluorescein isothiocyanate (FITC) mouse anti-human IFN-alpha2 25 tests...
Rabbit Anti-melatonin (different linkage) Polyclonal Antibody...
Gentamicin sulfate, 5g...
Biology Products: